(PRWEB) February 28, 2013
The coming years will see Japan pharma regaining its status as innovator driven with Edoxaban for Daiichi Sankyo, Canagliflozin for Mitsubishi Tanabe, and Dolutegravir for Shionogi bringing the good times back for the respective companies in 2013 and carrying enough potential to change global market dynamics in the anticoagulant, diabetes and HIV space resp. The massive $45b poured in acquiring innovation by Japanese companies does not justify its value as the key catalysts from Japan are in-house candidates.
Changing political scenario in Japan will accelerate the pace of reforms in Japan as recently; the Liberal Democratic Party (LDP) of Japan came back into power replacing the short tenure of the Democratic Party of Japan (DPJ). LDP was the pioneer initiator of major healthcare reforms with a focus on curbing healthcare costs by means of enhancing generic drugs penetration. This report discusses in details about the implications of these changes on Innovator and generic domestic Japanese pharma companies.
Global companies on the other hand are going to see a favorable scenario in coming years - expected launches in 2013-2014 from global companies will increase competition to domestic players mainly in the respiratory, oncology and rheumatoid arthritis therapy areas, and will increase overall market size of Diabetes and Osteoporosis markets.
Going forward, generic companies will continue to witness a growth story.
Leading players featured in this report include Daiichi Sankyo, Kyorin, Mitsubishi Tanabe, Shionogi, Eisai, Astellas, Chugai, Dainippon Sumitomo, Kyowa Hakko Kirin, Nippon Chemiphar, Sawai, Takeda, and Towa.
For more information please visit http://www.researchandmarkets.com/research/dz9d22/global
Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716